Case report of selumetinib as a novel therapy in a neurofibromatosis type 2-associated ependymoma

We report partial response (PR) to novel therapy with selumetinib in a patient with neurofibromatosis type 2 (NF2). A 25-year-old male presented with bilateral vestibular schwannomas, spinal cord intramedullary ependymomas, cranial and spinal meningiomas, spinal nerve root mixed schwannoma-neurofibr...

Descripción completa

Detalles Bibliográficos
Autores principales: Blackwood, Nigel, Zetzmann, Christopher, Trevino, Christopher R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696461/
http://dx.doi.org/10.1016/j.omtm.2023.101156

Ejemplares similares

Ejemplares similares